AU2017285995B2 - PRL3 antibody - Google Patents

PRL3 antibody Download PDF

Info

Publication number
AU2017285995B2
AU2017285995B2 AU2017285995A AU2017285995A AU2017285995B2 AU 2017285995 B2 AU2017285995 B2 AU 2017285995B2 AU 2017285995 A AU2017285995 A AU 2017285995A AU 2017285995 A AU2017285995 A AU 2017285995A AU 2017285995 B2 AU2017285995 B2 AU 2017285995B2
Authority
AU
Australia
Prior art keywords
prl
prl3
cancer
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017285995A
Other languages
English (en)
Other versions
AU2017285995A1 (en
Inventor
Qi Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of AU2017285995A1 publication Critical patent/AU2017285995A1/en
Application granted granted Critical
Publication of AU2017285995B2 publication Critical patent/AU2017285995B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017285995A 2016-06-14 2017-06-14 PRL3 antibody Active AU2017285995B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201604834P 2016-06-14
SG10201604834P 2016-06-14
PCT/SG2017/050300 WO2017217934A1 (en) 2016-06-14 2017-06-14 Prl3 antibody

Publications (2)

Publication Number Publication Date
AU2017285995A1 AU2017285995A1 (en) 2019-01-31
AU2017285995B2 true AU2017285995B2 (en) 2023-11-30

Family

ID=60663634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017285995A Active AU2017285995B2 (en) 2016-06-14 2017-06-14 PRL3 antibody

Country Status (10)

Country Link
US (1) US11155636B2 (enExample)
EP (1) EP3469003A4 (enExample)
JP (2) JP2019531254A (enExample)
KR (1) KR102451588B1 (enExample)
CN (1) CN109476759B (enExample)
AU (1) AU2017285995B2 (enExample)
BR (1) BR112018075901A2 (enExample)
CA (1) CA3025756A1 (enExample)
SG (1) SG11201811068YA (enExample)
WO (1) WO2017217934A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119110747A (zh) 2022-05-11 2024-12-10 国立研究开发法人产业技术综合研究所 氨分离膜及使用了其的氨分离方法
TW202532435A (zh) * 2023-11-30 2025-08-16 新加坡科技研究局 治療新生血管性眼疾之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136774A1 (en) * 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287644A1 (en) 2004-05-14 2005-12-29 Genesis Biotech Inc. Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
WO2006091326A1 (en) 2005-01-28 2006-08-31 Attogen Inc. Anti-prl-3 antibodies and methods of use thereof
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2011065923A1 (en) 2009-11-30 2011-06-03 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
WO2015119570A1 (en) * 2014-02-07 2015-08-13 Agency For Science, Technology And Research Prl-3 as a biomarker for the prognosis of cancer and a target for therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136774A1 (en) * 2007-05-03 2008-11-13 Agency For Science, Technology And Research Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Also Published As

Publication number Publication date
CA3025756A1 (en) 2017-12-21
CN109476759B (zh) 2022-11-08
US11155636B2 (en) 2021-10-26
KR20190024961A (ko) 2019-03-08
JP2022078202A (ja) 2022-05-24
BR112018075901A2 (pt) 2019-03-19
AU2017285995A1 (en) 2019-01-31
EP3469003A4 (en) 2020-07-29
US20200181283A1 (en) 2020-06-11
JP2019531254A (ja) 2019-10-31
EP3469003A1 (en) 2019-04-17
CN109476759A (zh) 2019-03-15
JP7408707B2 (ja) 2024-01-05
KR102451588B1 (ko) 2022-10-06
SG11201811068YA (en) 2019-01-30
WO2017217934A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
EP3212231B1 (en) Anti-tim-3 antibodies
AU2011255870B2 (en) Anti-human TROP-2 antibody having antitumor activity in vivo
US20190040136A1 (en) Anti-lag-3 antibodies
CA2960466C (en) Cancer cell-specific antibody, anticancer drug and cancer testing method
WO2016068801A1 (en) Anti-pd-1 antibodies
US20250115644A1 (en) Affinity-enhanced monmeric streptavidin chimeric antigen receptor (car)
WO2023219147A1 (ja) Ｃｃｒ８検出用新規抗ｃｃｒ８抗体
TW202116798A (zh) 類t細胞受體之抗體
JP7408707B2 (ja) Ｐｒｌ３抗体
TW202342528A (zh) 抗人類ｃｘｃｌ１抗體
HK40006061A (en) Prl3 antibody
HK40006061B (en) Prl3 antibody
NZ623464B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)